Pharming Group NV has raised €7.5 million in convertible debt that will help finance its activities while its lead product for hereditary angioedema, Rhucin, is being reviewed by the European Medicines Agency. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals
